03309 C-MER EYE
- 3.110
- -0.050-1.58%
C-MER EYE News
希瑪眼科：年度報告 2023
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
Xima Ophthalmology (03309) announced annual results. Profit attributable to shareholders was HK$61.98 million, turning a year-on-year loss into a profit
According to the Zhitong Finance App, Xima Ophthalmology (03309) announced annual results for the year ended December 31, 2023, with revenue of HK$1,924 million, up 11.1% year on year; the company's equity holders should have accounted for the profit of HK$61.98 million during the year, while the same period in 2022 recorded a loss of HK$21.875 million and a profit of HK4.94 cents per share. According to the announcement, total revenue in 2023 was HK$1,924 million, a slight increase of 11.1% over 2022, due to core medical service revenue in 2023 (including provision of ophthalmology services, provision of dental and other medical services, and sales
C-MER EYE: ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
C-mer Eye Care Holdings Foresses HK$65 Million in 2023 Profit
C-mer Eye Care Holdings (HKG:3309) expects a profit attributable to the equity holders of the Company in the range of HK$60.0 million to HK$65.0 million for the year ended Dec. 31, 2023, compared with
Changes in Hong Kong stocks | Hima Ophthalmology (03309) is expected to increase by more than 5%. Net profit last year was not less than HK$60 million and turned a year-on-year loss into profit
Hima Ophthalmology (03309) rose more than 5%. As of press release, it rose 5.35% to HK$3.15, with a turnover of HK$5.166,600.
GLONGHUI ANNOUNCEMENT SELECTION (HK Stock) | BOSS Direct Employment - W (02076.HK) Announces Annual Results Adjusted Net Profit Reaches 2.156 Billion Yuan; Total Revenue for the First Quarter Is Expected to Increase by 28.3% to 30.7%
[Today's Focus] BOSS Direct Employment-W (02076.HK) announces annual results with adjusted net profit of 2.56 billion yuan. Total revenue for the first quarter is expected to increase 28.3% to 30.7% BOSS Direct Employment-W (02076.HK) announced that revenue for the fourth quarter of 2023 was RMB 1,580.2 million, an increase of 46.0% over RMB 1,082.3 million in the same period of 2022. Revenue for the full year of 2023 was RMB 5,952.0 million, up 31 from RMB 4,511.1 million for the full year of 2022.
Hima Ophthalmology (03309.HK) Profit: Expected net profit of HK$60 million to HK$65 million in 2023
Gelonghui March 12 | Xima Ophthalmology (03309.HK) announced that according to the currently available unaudited financial data for the year ended 31 December 2023, the company is expected to turn a loss into a profit, bringing the profit attributable to the company's equity holders to HK$60 million to HK$65 million, while a loss attributable to equity holders was recorded at HK$21.9 million for the year ended 31 December 2022. Profit attributable to the company's equity holders is expected to increase, mainly due to the increase in revenue from medical services by more than 30% from HK$1.43 billion in FY2022 to FY2023
希瑪眼科：正面盈利預告
Hima Ophthalmology (03309.HK) plans to hold a board meeting on March 26 to approve annual results
Glonghui, March 8, 丨 Hima Ophthalmology (03309.HK) announced that the board of directors meeting will be held on March 26, 2024 (Tuesday) to approve (among other things) the publication of the annual results of the company and its subsidiaries for the year ended 31 December 2023 and consider proposals for payment of a final dividend (if any).
C-MER EYE: NOTICE OF BOARD MEETING
Changes in Hong Kong stocks | Hima Ophthalmology (03309) rose more than 6%, Shenzhen Aikangjian Hospital was included in the “Greater Bay Area Pilot Program for Elderly Health Care Vouchers”
Hima Ophthalmology (03309) rose by more than 6% and rose 6.53% at press time to report at HK$3.1 million, with a turnover of HK$3.05 million.
C-MER Dental Hospital Added to Greater Bay Area Elder Care Scheme
C-MER Eye Care's (HKG:3309) Shenzhen CKJ Stomatological Hospital has been added to the Elderly Health Care Voucher Greater Bay Area Pilot Scheme, making the facility one of seven institutions and the
Hima Ophthalmology (03309): Shenzhen Aikangjian Hospital was included in the “Greater Bay Area Pilot Program for Elderly Health Care Vouchers”
Hima Ophthalmology (03309) issued an announcement as the Hong Kong Special Administrative Region Government (Hong Kong Government, China) 2023...
Xima Ophthalmology (03309.HK) signed a strategic cooperation agreement with the Shenzhen Luohu District Government for the construction of the Luohu Port Hong Kong-style Port Hospital
Gelonghui, Feb. 19 | Hima Ophthalmology (03309.HK) announced that as part of the cross-border medical collaboration under the Hong Kong Special Administrative Region Government's 2023 Policy Address, the Hong Kong Government announced on February 19, 2024 that Shenzhen Aikangjian Dental Hospital has been included as one of the seven medical institutions under the Greater Bay Area Pilot Program for the Elderly. It is also the only dental hospital in the pilot program to cover the provision of dental services under the Guangdong-Hong Kong-Macao Greater Bay Area Health Care Voucher. Approximately 1.7 million eligible elderly people in Hong Kong are expected to benefit from the pilot scheme. In the process of selecting medical institutions in the Greater Bay Area for the pilot program, the Hong Kong Government
C-MER Eye Care Holdings (HKG:3309 Investor Three-year Losses Grow to 49% as the Stock Sheds HK$449m This Past Week
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But in any portfolio, there are likely to be some stocks that fall sho
C-MER Eye Care Holdings Repurchases 808,000 Shares
C-MER Eye Care Holdings (HKG:3309) bought back 808,000 shares on the market during the week of Nov. 13 to Nov. 17 for HK$3 million at between HK$3.68 and HK$3.81 apiece, a Friday filing said. The eye
Hima Ophthalmology (03309.HK) has repurchased 808,000 shares with a total value of HK$3 million
Gelonghui November 17丨Hima Ophthalmology (03309.HK) announced that on the five trading days ending the announcement date, the company had repurchased 808,000 shares from the market in accordance with the repurchase authorization, with a total value of HK$3 million (excluding brokerage fees, stamp duty and other expenses). The maximum price per repurchased share was HK$3.81 and the minimum repurchased price per share was HK$3.68. The company will then cancel the repurchased shares.
Hima Ophthalmology (03309) spent approximately HK$1,321,400 to repurchase 326,000 shares on November 16
Hima Ophthalmology (03309) announced that it spent approximately HK$1,321,400 on November 16, 2023...
Hima Ophthalmology (03309.HK) spent HK$1,016,000 to repurchase 268,000 shares on November 15
Gelonghui November 15 | Hima Ophthalmology (03309.HK) announced that 268,000 shares were repurchased at a cost of HK$1,016,000 on November 15, at a price of HK$3.74-3.81 per share.
Analysis
Price Target
No Data
